In this issue:
Allogeneic transplant rapidly resolves osteosclerosis
SIMPLIFY-2: Better management of anaemia with momelotinib vs continued ruxolitinib
Effectiveness of ruxolitinib ± IFN-α
Pacritinib response is prognostic for survival
EBMT expert consensus: determining transplant eligibility in challenging populations
Early intervention with ruxolitinib improves spleen response
Ruxolitinib does not increase the risk of secondary malignancy
Please login below to download this issue (PDF)